<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04752475</url>
  </required_header>
  <id_info>
    <org_study_id>AAAT2525</org_study_id>
    <nct_id>NCT04752475</nct_id>
  </id_info>
  <brief_title>Lasix for the Prevention of De Novo Postpartum Hypertension</brief_title>
  <acronym>LAPP</acronym>
  <official_title>Lasix for the Prevention of De Novo Postpartum Hypertension: A Randomized Controlled Trial (LAPP Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective: To evaluate whether oral furosemide can help prevent de novo postpartum&#xD;
      hypertension (new-onset high blood pressure after delivery) by reducing blood pressure after&#xD;
      delivery in high-risk women.&#xD;
&#xD;
      Secondary objectives: To evaluate whether oral furosemide administered to high-risk women&#xD;
      after delivery can reduce the frequency of postpartum hypertensive episodes, the need for&#xD;
      antihypertensive therapy, the risk of postpartum preeclampsia, and the incidence of severe&#xD;
      maternal morbidity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypertensive disorders of pregnancy are one of the leading causes of maternal morbidity and&#xD;
      mortality worldwide. The majority of clinical research has focused on pregnancy-related&#xD;
      hypertension that develops in the antenatal period, while studies of the incidence, risk&#xD;
      factors, and prevention of postpartum hypertension are limited. In particular, there is a&#xD;
      paucity of data about the clinical entity known as de novo postpartum hypertension, in which&#xD;
      women who are normotensive throughout pregnancy and delivery subsequently go on to develop&#xD;
      high blood pressure in the immediate to late postpartum period. Of those with postpartum&#xD;
      preeclampsia, 33-69% were normotensive antepartum.&#xD;
&#xD;
      Early identification and treatment of antepartum preeclampsia has been shown to decrease some&#xD;
      severe maternal outcomes. Conversely, women with de novo postpartum hypertensive disorders&#xD;
      remain among the highest risk for severe maternal morbidity due to decreased surveillance and&#xD;
      lack of data regarding preventive therapies and interventions. Evidence from multiple&#xD;
      randomized controlled trials have demonstrated a benefit in the use of oral loop-diuretics in&#xD;
      decreasing postpartum systolic blood pressure, promoting faster normalization of blood&#xD;
      pressure, and decreasing the need for antihypertensive therapy in women with an antenatal&#xD;
      diagnosis of preeclampsia. Biological plausibility suggests that loop-diuretic therapy may&#xD;
      similarly mitigate the normal physiologic mechanism that has been implicated in the&#xD;
      pathogenesis of hypertensive complications after delivery in women at risk for de novo&#xD;
      postpartum hypertension.&#xD;
&#xD;
      This study is a double-blind randomized placebo-controlled trial of 82 high-risk women to&#xD;
      assess whether treatment with oral Lasix (furosemide) after delivery reduces blood pressure&#xD;
      at the time of discharge. Women at high risk for de novo postpartum hypertension will be&#xD;
      randomized to a five-day course of either 20 mg oral Lasix (furosemide) or placebo once daily&#xD;
      initiated after delivery. Women will be monitored through their routine 2-week and 6-week&#xD;
      postpartum visits, during which times hypertensive complications and adverse effects of&#xD;
      therapy will be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study is a randomized controlled clinical trial of 82 women with one or more high-risk factors for de novo postpartum hypertension, randomized to one of two arms: 20 mg PO Lasix (furosemide) daily for 5 days or identical-appearing daily placebo for 5 days.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Consenting women will be assigned to Lasix (furosemide) or placebo in a 1:1 ratio according to a randomization scheme achieved using a computer generated algorithm. Neither the participant nor the clinical care team will be aware of the allocation arm.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean arterial blood pressure (MAP)</measure>
    <time_frame>24 hours prior to discharge through discharge, up to 7 days</time_frame>
    <description>Difference in MAP averaged over the 24 hours prior to discharge or the 24 hours prior to antihypertensive therapy initiation (whichever occurs first)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of de novo postpartum preeclampsia</measure>
    <time_frame>Discharge (up to 7 days), 2 weeks postpartum, 6 weeks postpartum</time_frame>
    <description>Proportion of participants who develop de novo postpartum hypertension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of hypertensive episodes</measure>
    <time_frame>Discharge (up to 7 days), 2 weeks postpartum, 6 weeks postpartum</time_frame>
    <description>Mean frequency of recorded blood pressures that are elevated (&gt;140 systolic OR &gt;90 diastolic)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of magnesium sulfate administration</measure>
    <time_frame>Discharge (up to 7 days), 2 weeks postpartum, 6 weeks postpartum</time_frame>
    <description>Proportion of participants who receive intravenous magnesium sulfate for seizure prophylaxis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of initiation of antihypertensives</measure>
    <time_frame>Discharge (up to 7 days), 2 weeks postpartum, 6 weeks postpartum</time_frame>
    <description>Proportion of participants receiving intravenous antihypertensive therapy and initiated on oral hypertensive therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discharge</measure>
    <time_frame>Randomization through discharge, up to 7 days</time_frame>
    <description>Time until discharge from the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of severe maternal morbidity</measure>
    <time_frame>Discharge (up to 7 days), 2 weeks postpartum, 6 weeks postpartum</time_frame>
    <description>Proportion of participants experiencing severe maternal morbidity (e.g. seizure, stroke, Posterior reversible encephalopathy syndrome (PRES), death, etc.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of triage or Emergency Department (ED) presentation/readmission</measure>
    <time_frame>2 weeks postpartum, 6 weeks postpartum</time_frame>
    <description>Mean frequency of triage or ED presentation/readmission for hypertensive-related complaints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breastfeeding continuation rate</measure>
    <time_frame>2 weeks postpartum, 6 weeks postpartum</time_frame>
    <description>Proportion of participants continuing to breastfeed of those who initiated breastfeeding after delivery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Postpartum Pregnancy-Induced Hypertension</condition>
  <condition>Postpartum Preeclampsia</condition>
  <condition>Hypertension, Pregnancy-Induced</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Lasix (furosemide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Furosemide 20 mg, oral, once daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical-appearing placebo, oral, once daily for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <description>Furosemide 20 mg pill taken daily for 5 days</description>
    <arm_group_label>Lasix (furosemide)</arm_group_label>
    <other_name>Lasix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identical-appearing placebo pill taken daily for 5 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Postpartum women&#xD;
&#xD;
          -  No antenatal diagnosis of hypertensive disorder of pregnancy at the time of admission&#xD;
             for delivery, defined as existing chronic hypertension diagnosis or documented blood&#xD;
             pressure of ≥140 systolic OR ≥90 diastolic on at least 2 occasions at least 4 hours&#xD;
             apart prior to delivery admission who do not go on to get magnesium for seizure&#xD;
             prophylaxis by the time of delivery&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  English or Spanish speakers&#xD;
&#xD;
          -  One or more high risk factors for development of de novo postpartum hypertension&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-English or Spanish speakers&#xD;
&#xD;
          -  Women with a contraindication to diuretic therapy&#xD;
&#xD;
          -  Women who have used diuretics in the two weeks prior to delivery&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia Gyamfi-Bannerman, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California San Diego Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Russell S Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ukachi N Emeruwa, MD, MPH</last_name>
    <phone>212-305-6293</phone>
    <email>une2001@cumc.columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ukachi N Emeruwa, MD, MPH</last_name>
      <phone>646-908-9050</phone>
      <email>une2001@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Russell S Miller, MD</last_name>
      <phone>212-305-3151</phone>
      <email>rsm20@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Cynthia Gyamfi-Bannerman, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Russell S Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ukachi N Emeruwa, MD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Clark SL, Belfort MA, Dildy GA, Herbst MA, Meyers JA, Hankins GD. Maternal death in the 21st century: causes, prevention, and relationship to cesarean delivery. Am J Obstet Gynecol. 2008 Jul;199(1):36.e1-5; discussion 91-2. e7-11. doi: 10.1016/j.ajog.2008.03.007. Epub 2008 May 2.</citation>
    <PMID>18455140</PMID>
  </reference>
  <reference>
    <citation>ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. Obstet Gynecol. 2019 Jan;133(1):1. doi: 10.1097/AOG.0000000000003018.</citation>
    <PMID>30575675</PMID>
  </reference>
  <reference>
    <citation>Al-Safi Z, Imudia AN, Filetti LC, Hobson DT, Bahado-Singh RO, Awonuga AO. Delayed postpartum preeclampsia and eclampsia: demographics, clinical course, and complications. Obstet Gynecol. 2011 Nov;118(5):1102-1107. doi: 10.1097/AOG.0b013e318231934c.</citation>
    <PMID>21979459</PMID>
  </reference>
  <reference>
    <citation>Filetti LC, Imudia AN, Al-Safi Z, Hobson DT, Awonuga AO, Bahado-Singh RO. New onset delayed postpartum preeclampsia: different disorders? J Matern Fetal Neonatal Med. 2012 Jul;25(7):957-60. doi: 10.3109/14767058.2011.601365. Epub 2011 Aug 16.</citation>
    <PMID>21740315</PMID>
  </reference>
  <reference>
    <citation>Matthys LA, Coppage KH, Lambers DS, Barton JR, Sibai BM. Delayed postpartum preeclampsia: an experience of 151 cases. Am J Obstet Gynecol. 2004 May;190(5):1464-6.</citation>
    <PMID>15167870</PMID>
  </reference>
  <reference>
    <citation>Sibai BM. Diagnosis, prevention, and management of eclampsia. Obstet Gynecol. 2005 Feb;105(2):402-10. Review.</citation>
    <PMID>15684172</PMID>
  </reference>
  <reference>
    <citation>Lubarsky SL, Barton JR, Friedman SA, Nasreddine S, Ramadan MK, Sibai BM. Late postpartum eclampsia revisited. Obstet Gynecol. 1994 Apr;83(4):502-5. Review.</citation>
    <PMID>8134057</PMID>
  </reference>
  <reference>
    <citation>Bigelow CA, Pereira GA, Warmsley A, Cohen J, Getrajdman C, Moshier E, Paris J, Bianco A, Factor SH, Stone J. Risk factors for new-onset late postpartum preeclampsia in women without a history of preeclampsia. Am J Obstet Gynecol. 2014 Apr;210(4):338.e1-338.e8. doi: 10.1016/j.ajog.2013.11.004. Epub 2013 Nov 7.</citation>
    <PMID>24211478</PMID>
  </reference>
  <reference>
    <citation>Chames MC, Livingston JC, Ivester TS, Barton JR, Sibai BM. Late postpartum eclampsia: a preventable disease? Am J Obstet Gynecol. 2002 Jun;186(6):1174-7.</citation>
    <PMID>12066093</PMID>
  </reference>
  <reference>
    <citation>Ascarelli MH, Johnson V, McCreary H, Cushman J, May WL, Martin JN Jr. Postpartum preeclampsia management with furosemide: a randomized clinical trial. Obstet Gynecol. 2005 Jan;105(1):29-33.</citation>
    <PMID>15625138</PMID>
  </reference>
  <reference>
    <citation>Veena P, Perivela L, Raghavan SS. Furosemide in postpartum management of severe preeclampsia: A randomized controlled trial. Hypertens Pregnancy. 2017 Feb;36(1):84-89. doi: 10.1080/10641955.2016.1239735. Epub 2016 Nov 11.</citation>
    <PMID>27835048</PMID>
  </reference>
  <reference>
    <citation>Perdigao JL, Lewey J, Hirshberg A, et al. LB 4: Furosemide for Accelerated Recovery of Blood Pressure Postpartum: a randomized placebo controlled trial (FoR BP). American Journal of Obstetrics &amp; Gynecology. 2020;222(1):S759-S760.</citation>
  </reference>
  <reference>
    <citation>Atterbury JL, Groome LJ, Hoff C. Blood pressure changes in normotensive women readmitted in the postpartum period with severe preeclampsia/eclampsia. J Matern Fetal Med. 1996 Jul-Aug;5(4):201-5.</citation>
    <PMID>8796794</PMID>
  </reference>
  <reference>
    <citation>Hirshberg A, Downes K, Srinivas S. Comparing standard office-based follow-up with text-based remote monitoring in the management of postpartum hypertension: a randomised clinical trial. BMJ Qual Saf. 2018 Nov;27(11):871-877. doi: 10.1136/bmjqs-2018-007837. Epub 2018 Apr 27.</citation>
    <PMID>29703800</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Russell Miller</investigator_full_name>
    <investigator_title>Sloane Hospital for Women Associate Professor of Prenatal Pediatrics (in Obstetrics and Gynecology)</investigator_title>
  </responsible_party>
  <keyword>De novo postpartum hypertension</keyword>
  <keyword>New-onset postpartum hypertension</keyword>
  <keyword>Lasix</keyword>
  <keyword>Furosemide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Hypertension, Pregnancy-Induced</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

